The global T-cell therapy market is anticipated to grow at a CAGR of around 20.9% during the forecast period 2020 to 2027 and to reach around US$ 17.3 Bn by 2027.
Rapid advancements in immunotherapy, increasing investment by major players for R&D activities, and focus on the development of protein and small molecule-based treatments to adoptive therapies are major factors expected to drive the growth of the global T-cell therapy market. Gradual increase in number of patients suffering from chronic cancer and increasing clinical trials by major players are factors expected to boost the growth of target market. According to U.S. Department of Health & Human Services each year in the United States, about 24,000 men and 10,000 women get liver cancer, and about 18,000 men and 9,000 women die from the disease. Currently, there are 362 investigational cell and gene therapies currently in clinical development, a 20 percent increase from 2018, according to a March report from Pharmaceutical Research and Manufacturers of America (PhRMA). Increasing product pipeline and approvals for novel products from the government is expected to augment the T-cell therapy market growth.
In 2020, the U.S. Food and Drug Administration (FDA) approved “Tecartus” (brexucabtagene autoleucel), cell-based gene therapy for treatment of adult patients diagnosed with mantle cell lymphoma (MCL) who have not responded to or who have relapsed following other kinds of treatment. Tecartus, a chimeric antigen receptor (CAR) T cell therapy, is the first cell-based gene therapy approved by the FDA for the treatment of MCL.
In 2021, OrganaBio a global player in gene therapy launched a new cell product, ImmunoPAC-T-CB T-cells, designed to support the development of allogeneic immune cell-based therapies, such as chimeric antigen receptor (CAR) T-cells. This product launch is expected to help the company to enhance the product portfolio and increase the revenue share.
In 2020, Sanofi a global biopharmaceutical company acquired Kiadis another biopharmaceutical company for US$ 359 Mn. The acquisition is expected to help the company in development of NK cell-based medicines for the treatment of patients undergoing hematopoietic stem cell transplant, liquid and solid tumors, and other infectious diseases.
In 2020, Astellas Pharma Inc a pharmaceutical company acquired Xyphos and its next-generation take on CAR-T therapies. This acquisition is expected to help the company to enhance the business presence and increase the revenue share.
Factors such as high cost associated to R&D activities and therapy are expected to hamper the growth of global T-cell therapy market. In addition, stringent government regulations related to product approval is expected to challenge the growth of T-cell therapy market. However, increasing investment by major players, introduction of innovative solutions and focus on expansion of manufacturing facilities are factors expected to create new opportunities for players operating in the T-cell therapy market over the forecast period. In addition, increasing partnership between regional and international players and focus on tracking the untapped market in developing countries are factors expected to support the revenue transaction of the target market.
Segment Analysis By Region
The market in North America is expected to account for major revenue share in the global T-cell therapy market due to high patient pool suffering from liver cancer. In addition, availability of advanced healthcare infrastructure for R&D activities and introduction of new drugs are factors expected to boost the target market growth.
Increasing merger & acquisition activities by major players in order to enhance the business presence and increase the revenue share is expected to augment the growth of T-cell therapy regional market.
The global market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
T-cell Therapy Market Segment Analysis, 2019
The global T-cell therapy market is segmented into modality, therapy type, and indication. The modality segment is bifurcated into research and commercialized. Among modality type the research segment is expected to account for major revenue share in the global T-cell therapy market. The therapy type segment is divided into CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based. Among indication type the hematologic malignancies segment is expected to account for major revenue share in the target market. Players operating in the global T-cell therapy market are Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., Sorrento Therapeutics, Fate Therapeutics, Pfizer Inc., and Amgen.
Market By Modality
Market By Therapy Type
CAR T-cell Therapy
T-Cell Receptor (TCR)-based
Tumor Infiltrating Lymphocytes (TIL)-based
Market By Indication
• Brain & Central Nervous System
• Liver Cancer
Market By Geography
• Rest of Europe
• South Korea
• Rest of Asia-Pacific
• Rest of Latin America
Middle East & Africa
• South Africa
• Rest of Middle East & Africa
The global T-cell therapy market in 2027 is expected to be above US$ 17.3 Bn.
The CAGR of the global T-cell therapy market from 2020-2027 is above 20.9%.
In modality the research segment is growing at faster pace.
Rapid advancements in immunotherapy, increasing investment by major players for R&D activities and focus on development of protein and small molecule-based treatments to adoptive therapies are major factors expected to drive the growth of global T-cell therapy market.
In the global market the Asia Pacific region is expected to grow faster.
Some of the players considered in the report scope are Novartis AG, Merck KGaA, Gilead Sciences Inc., TCR2 Therapeutics Inc., Bluebird Bio Inc., and Sorrento Therapeutics.
The North America is expected to account for major revenue share in the global market.